BGC > Product Search > Tofacitinib citrate

Molecular Formula: C16H20N6O.C6H8O7
Molecular Weight: 504.497
WGKGermany: 3
HS Code: 29335990

Molecular Formula: C16H20N6O.C6H8O7
Molecular Weight: 504.497
WGKGermany: 3
HS Code: 29335990

Molecular Formula: C16H20N6O.C6H8O7
Molecular Weight: 504.497
WGKGermany: 3
HS Code: 29335990

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

EINECS :638-826-4
Molecular formula :C16H20N6O•C6H8O7

Description :
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source:

• Molecular Weight :504.5
• Melting Point :198-202 °C (dec.)
• Purity :0.99

Molecular Formula :
C22H28N6O8
Canonical SMILES :
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI :
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey :
SYIKUFDOYJFGBQ-YLAFAASESA-N
Solubility :
In Vitro: DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance :
White to Off-white Solid
Application :
Janus Kinase Inhibitors
Storage : Powder: 3 years -20°C In solvent: 2 years -80°C
Synonyms :
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
https://www.bocsci.com/product/tofacitinib-citrate-cas-540737-29-9-461917.html

More details are to be found here

Description :
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source:

• Molecular Weight :504.5
• Melting Point :198-202 °C (dec.)
• Purity :0.99

Molecular Formula :
C22H28N6O8
Canonical SMILES :
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI :
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey :
SYIKUFDOYJFGBQ-YLAFAASESA-N
Solubility :
In Vitro: DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance :
White to Off-white Solid
Application :
Janus Kinase Inhibitors
Storage : Powder: 3 years -20°C In solvent: 2 years -80°C
Synonyms :
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
https://www.bocsci.com/product/tofacitinib-citrate-cas-540737-29-9-461917.html

More details are to be found here

Description :
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source:

• Molecular Weight :504.5
• Melting Point :198-202 °C (dec.)
• Purity :0.99

Molecular Formula :
C22H28N6O8
Canonical SMILES :
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI :
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey :
SYIKUFDOYJFGBQ-YLAFAASESA-N
Solubility :
In Vitro: DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance :
White to Off-white Solid
Application :
Janus Kinase Inhibitors
Storage : Powder: 3 years -20°C In solvent: 2 years -80°C
Synonyms :
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
https://www.bocsci.com/product/tofacitinib-citrate-cas-540737-29-9-461917.html

More details are to be found here

Description :
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source:

• Molecular Weight :504.5
• Melting Point :198-202 °C (dec.)
• Purity :0.99

Molecular Formula :
C22H28N6O8
Canonical SMILES :
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI :
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey :
SYIKUFDOYJFGBQ-YLAFAASESA-N
Solubility :
In Vitro: DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance :
White to Off-white Solid
Application :
Janus Kinase Inhibitors
Storage : Powder: 3 years -20°C In solvent: 2 years -80°C
Synonyms :
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
https://www.bocsci.com/product/tofacitinib-citrate-cas-540737-29-9-461917.html

More details are to be found here

Description :
Tofacitinib (trade name Xeljanz, formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved for the treatment of rheumatoid arthritis (RA) in the United States and is being studied for treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as for the prevention of organ transplant rejection. (source:

• Molecular Weight :504.5
• Melting Point :198-202 °C (dec.)
• Purity :0.99

Molecular Formula :
C22H28N6O8
Canonical SMILES :
CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI :
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1
InChIKey :
SYIKUFDOYJFGBQ-YLAFAASESA-N
Solubility :
In Vitro: DMSO : ≥ 122.5 mg/mL (242.82 mM) H2O : 5 mg/mL (9.91 mM; Need ultrasonic and warming)
Appearance :
White to Off-white Solid
Application :
Janus Kinase Inhibitors
Storage : Powder: 3 years -20°C In solvent: 2 years -80°C
Synonyms :
CP-690550; CP 690550; CP690550; Tofacitinib; tasocitinib.
https://www.bocsci.com/product/tofacitinib-citrate-cas-540737-29-9-461917.html

More details are to be found here